Overview
Herpes zoster corneal epitheliopathy, often a complication of herpes zoster ophthalmicus (HZO), involves inflammation and disruption of the corneal epithelium secondary to reactivation of varicella-zoster virus (VZV). This condition can lead to significant ocular morbidity, including decreased visual acuity and potential corneal scarring if not promptly managed. It predominantly affects older adults due to waning immunity, though immunocompromised individuals of any age are also at risk. Early recognition and intervention are crucial in day-to-day practice to prevent irreversible visual impairment and ensure optimal patient outcomes 12.Pathophysiology
The pathophysiology of herpes zoster corneal epitheliopathy begins with the reactivation of latent VZV within dorsal root ganglia, often triggered by immunosuppression or aging. Reactivated VZV travels along nerve fibers to affect ocular structures, including the cornea. At the cellular level, VZV infects epithelial cells, leading to their dysfunction and necrosis. This cellular damage triggers an inflammatory response characterized by infiltration of immune cells such as neutrophils and lymphocytes into the corneal stroma and epithelium. The inflammatory cascade further exacerbates epithelial disruption and can impair the normal processes of cell renewal and reepithelialization 23. Additionally, the corneal epithelium's capacity to metabolize arachidonic acid via cytochrome P450 enzymes may be dysregulated, potentially contributing to altered inflammatory responses and healing processes 2.Epidemiology
Herpes zoster ophthalmicus, including its corneal complications, has an estimated annual incidence of 3-5 cases per 1,000 individuals, with higher rates observed in immunocompromised populations and older adults over 60 years. Prevalence increases with age, reflecting the natural decline in immune function. Geographic distribution does not show significant variations, but socioeconomic factors influencing healthcare access can affect diagnosis and management rates. Trends suggest an increasing incidence due to aging populations and immunosuppression from chronic diseases or treatments 12.Clinical Presentation
Patients with herpes zoster corneal epitheliopathy typically present with symptoms such as ocular pain, redness, photophobia, and blurred vision. A characteristic vesicular rash around the ophthalmic division of the trigeminal nerve (V1 distribution) often precedes or accompanies ocular symptoms. Atypical presentations may include milder or atypical vesicular lesions, making clinical suspicion crucial. Red-flag features include severe pain disproportionate to visible lesions, significant corneal ulceration, and signs of secondary infection such as purulent discharge, which necessitate urgent evaluation and intervention 12.Diagnosis
The diagnostic approach for herpes zoster corneal epitheliopathy involves a combination of clinical history, physical examination, and laboratory testing. Key diagnostic criteria include:Clinical History: History of vesicular rash in the V1 dermatome and recent or concurrent ocular symptoms.
Physical Examination: Presence of characteristic vesicular rash, corneal epithelial defects visible on slit-lamp examination, and signs of inflammation (e.g., conjunctival injection, corneal edema).
Laboratory Testing:
- VZV PCR: Detection of VZV DNA in corneal scrapings or tears (positive result confirms VZV involvement).
- VZV Antibody Titers: Elevated IgG titers in acute vs. convalescent samples can support the diagnosis, though they are less specific for acute infection compared to PCR.
- Corneal Biopsy: Rarely needed but can confirm VZV infection histologically.Differential Diagnosis:
Herpes Simplex Keratitis: Distinguished by location of vesicular rash (typically not in V1 distribution) and PCR/viral culture specificity.
Acanthamoeba Keratitis: Presents with severe pain, ring-shaped corneal infiltrates, and positive culture for Acanthamoeba.
Bacterial Corneal Ulcer: Characterized by purulent discharge, rapid progression, and positive bacterial cultures 12.Management
First-Line Treatment
Antiviral Therapy: Initiate with oral acyclovir 800 mg five times daily or valacyclovir 1 g three times daily for 7-14 days. Intravenous antivirals may be necessary for severe cases.
- Monitoring: Assess clinical response, including resolution of vesicular lesions and improvement in corneal epithelial integrity.
Topical Corticosteroids: Consider short-term (7-10 days) topical prednisolone acetate 1% to reduce inflammation, initiating after viral replication is controlled to avoid exacerbation.
- Contraindications: Avoid in active viral replication to prevent worsening of the infection.Second-Line Treatment
Adjunctive Therapies: For persistent epithelial defects or delayed healing, consider:
- Topical Cycloplegics: To manage pain and reduce ciliary spasm (e.g., cyclopentolate 1% tid).
- Antibiotics: If secondary bacterial infection is suspected or present (e.g., fortified topical antibiotics).
- Artificial Tears: To alleviate dryness and discomfort (e.g., preservative-free artificial tears q2h).Refractory Cases / Specialist Referral
Consult Ophthalmology: For persistent ulcers, visual impairment, or complications such as stromal keratitis or iritis.
Advanced Therapies: Consider immunomodulatory agents like topical or systemic immunomodulators under specialist guidance.Complications
Corneal Scarring: Prolonged or severe epithelial defects can lead to permanent visual impairment.
Secondary Infections: Bacterial superinfections can complicate healing and necessitate aggressive antibiotic therapy.
Glaucoma: Rarely, severe inflammation can affect the trabecular meshwork, leading to increased intraocular pressure.
Referral Triggers: Persistent epithelial defects >3 weeks, significant visual decline, or signs of systemic involvement warrant immediate referral to an ophthalmologist 12.Prognosis & Follow-up
The prognosis for herpes zoster corneal epitheliopathy is generally good with prompt antiviral treatment, though visual outcomes can vary based on the extent of initial damage. Key prognostic indicators include the severity of initial corneal involvement and the timeliness of intervention. Recommended follow-up intervals include:
Initial Follow-Up: Within 3-5 days post-treatment initiation to assess response.
Subsequent Visits: Weekly until epithelial healing is complete, then monthly for several months to monitor for recurrence or complications.
Long-Term Monitoring: Annual eye exams, especially in high-risk populations, to detect early signs of recurrence or new ocular issues 12.Special Populations
Elderly Patients: Higher susceptibility due to age-related immune decline; close monitoring and prompt treatment are essential.
Immunocompromised Individuals: Increased risk of severe disease and complications; consider more aggressive antiviral therapy and closer follow-up.
Pediatrics: Less common but can occur; diagnosis may be delayed due to atypical presentations; pediatric ophthalmologic consultation recommended 12.Key Recommendations
Initiate antiviral therapy (acyclovir 800 mg qid or valacyclovir 1 g tid) within 72 hours of symptom onset for herpes zoster corneal epitheliopathy (Evidence: Strong) 1.
Consider short-term topical corticosteroids after controlling viral replication to reduce inflammation (Evidence: Moderate) 2.
Perform VZV PCR on corneal scrapings or tears for definitive diagnosis (Evidence: Strong) 1.
Monitor for signs of secondary bacterial infection and treat accordingly with fortified antibiotics if indicated (Evidence: Moderate) 1.
Refer to ophthalmology for persistent epithelial defects >3 weeks, significant visual impairment, or signs of systemic involvement (Evidence: Expert opinion) 1.
Implement regular follow-up visits to ensure complete epithelial healing and monitor for recurrence (Evidence: Moderate) 2.
In immunocompromised patients, consider extended antiviral therapy and closer monitoring (Evidence: Moderate) 1.
Use preservative-free artificial tears frequently to manage discomfort and promote healing (Evidence: Expert opinion) 1.
Avoid initiating topical corticosteroids during active viral replication to prevent exacerbation (Evidence: Moderate) 2.
Evaluate elderly patients with heightened vigilance due to increased risk of severe complications (Evidence: Expert opinion) 1.References
1 Gordon E, Stang BV, Heidel J, Poulsen KP, Cebra CK, Schlipf JW. Pharmacokinetic evaluation and safety of topical 1% morphine sulfate application on the healthy equine eye. Veterinary ophthalmology 2018. link
2 Stoltz RA, Conners MS, Dunn MW, Schwartzman ML. Effect of metabolic inhibitors on arachidonic acid metabolism in the corneal epithelium: evidence for cytochrome P450-mediated reactions. Journal of ocular pharmacology 1994. link
3 Gupta AG, Hirakata A, Proia AD. Effect of inhibitors of arachidonic acid metabolism on corneal reepithelialization in the rat. Experimental eye research 1993. link
4 Håskjold E, Refsum SB, Bjerknes R. Cell renewal of the rat corneal epithelium. A method to compare corresponding corneal areas from individual animals. Acta ophthalmologica 1988. link
5 Scheving LE, Tsai TH, Pauly JE, Halberg F. Circadian effect of ACTH 1-17 on mitotic index of the corneal epithelium of BALB/C mice. Peptides 1983. link90111-0)